Loading…
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $517M | $90M | $66M | $127M | 5.1% | 16.0% | 174.9% |
| 2024 | $446M | $49M | $24M | $64M | 2.1% | 23.5% | -132.4% |
| 2023 | $361M | $-49M | $-74M | $34M | -7.1% | 21.8% | 103.5% |
| 2022 | $297M | $-10M | $-37M | $-1M | -3.4% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 296.54 | 361.05 | 445.76 | 517.14 |
| Cost Of Revenue | - | 120.86 | 131.37 | 147.62 | 154.61 |
| Gross Profit | - | 175.68 | 229.68 | 298.14 | 362.53 |
| Operating Expense | - | 211.02 | 247.13 | 278.64 | 284.25 |
| Operating Income | - | -35.34 | -17.45 | 19.51 | 78.28 |
| EBITDA | - | -10.30 | -49.41 | 49.20 | 89.62 |
| EBIT | - | -36.23 | -76.60 | 25.75 | 68.20 |
| Pretax Income | - | -36.43 | -76.61 | 25.74 | 68.20 |
| Tax Provision | - | 0.13 | -2.21 | 1.61 | 1.85 |
| Net Income | - | -36.56 | -74.40 | 24.14 | 66.35 |
| Net Income Common Stockholders | - | -36.56 | -74.40 | 24.14 | 66.35 |
| Total Expenses | - | 331.88 | 378.50 | 426.25 | 438.86 |
| Interest Expense | - | 0.20 | 0.02 | 0 | 0 |
| Interest Income | - | 1.97 | 7.34 | 11.15 | 12.72 |
| Research And Development | - | 40.60 | 57.30 | 69.29 | 70.81 |
| Selling General And Administration | - | 170.76 | 187.72 | 206.04 | 210.95 |
| Normalized EBITDA | - | -7.18 | 18.22 | 54.62 | 112.86 |
| Normalized Income | - | -34.09 | -8.73 | 29.21 | 88.97 |
| Market Cap | 2,739.27 | 2,739.27 | 2,739.27 | 2,739.27 | 2,739.27 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Veracyte, Inc.this co. | VCYT | $2.7B | 41.28↑ premium | 2.09 | 5.1% | 26.96 |
| ICU Medical, Inc. | ICUI | $3.0B | 4261.68 | 1.47 | 0.0% | 13.89 |
| Integer Holdings Corporation | ITGR | $3.0B | 28.79 | 1.69 | 5.9% | 14.55 |
| Organon & Co. | OGN | $2.9B | 15.67 | 3.90 | 24.9% | 8.53 |
| Prestige Consumer Healthcare Inc. | PBH | $2.9B | 13.00 |
| - |
| - |
| - |
| - |
| 1.52 |
| 11.7% |
| 10.32 |
| Privia Health Group, Inc. | PRVA | $2.9B | 130.67 | 4.06 | 3.1% | 57.20 |
| National HealthCare Corporation | NHC | $2.7B | 22.47 | 2.52 | 11.2% | 12.59 |
| LeMaitre Vascular, Inc. | LMAT | $2.6B | 44.90 | 6.59 | 14.7% | 30.28 |
| Phibro Animal Health Corporation | PAHC | $2.2B | 46.33 | 7.83 | 16.9% | 19.95 |
| Peer Median | - | 36.84 | 3.21 | 11.5% | 14.22 | |